SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (664)3/23/1999 3:43:00 PM
From: Rick Strange  Read Replies (1) | Respond to of 1386
 
Todays press release makes mention of "The recent completion of a successful Phase II clinical study..." Does this mean that they have completed the TBI study or is this just the completion of part 2 of that study?

If it is the completion of the whole TBI study and results confirm the first two parts, PARS is in a very good position to deal with potential partners on HU-211. Can anyone confirm that this Phase II study is complete?



To: David Israel-Rosen who wrote (664)3/23/1999 4:31:00 PM
From: LLCF  Read Replies (2) | Respond to of 1386
 
<We are looking at the conversion and sale of stock by CC. This shall end soon lifting the stock HIGHER>

I would think they are converting some every day... the strike price is moving up each day... while moving up they can short it guaranteed of converting at a lower price that nite because of the 5 day average... so IMO this move will cause conversion, which in turn will eat up their "shorting" and when finished the stock can breath.

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News